NRG Oncology
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, NRG Oncology sits in the top decile of US sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count).
NRG Oncology: 64 sponsored US clinical trials, 30 recruiting.
NRG Oncology sponsors 64 registered US clinical trials on ClinicalTrials.gov, 30 of them currently recruiting, and 15 completed. 31 of these trials are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Adenocarcinoma, with 7 trials.
Top-decile sponsor footprint
NRG Oncology ranks in the top decile of sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 20 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
64 total, page 2 of 2
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NCT03180294
Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery
NCT03188393
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02713386
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT02728258
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer
NCT02635009
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
NCT02360215
Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery
NCT02315469
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NCT02316548
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
NCT02364557
Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer
NCT02254278
Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
NCT02200042
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
NCT02206334
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT02186847
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 21 |
| Phase 3 | 31 |
Therapeutic Areas
What is open in the NRG Oncology pipeline
30 recruiting of 64 indexed (47% open); 15 completed (23%).
Phase mix: 31 late (III/IV) vs 26 early (I/II) (balanced across stages).
Top condition: Prostate Adenocarcinoma (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NRG Oncology: open-pipeline peers nationwide
Peers matched on 64 registered trials and 47% open enrollment, not the therapeutic-area sidebar.
NRG Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 64 trials (± recruiting share)
- Cephalon · 64 trials · 0% recruiting
- CooperVision · 64 trials · 3% recruiting
- University of Houston · 64 trials · 20% recruiting
- Washington State University · 64 trials · 30% recruiting
Sponsors near 47% open enrollment (± trial volume)
- University of Texas, El Paso · 47% recruiting · 17 trials
- North Carolina State University · 47% recruiting · 19 trials
- Nader Sanai · 46% recruiting · 13 trials
- Praxis Precision Medicines · 46% recruiting · 13 trials
Related
What to do with this NRG Oncology page
64 registered trials is a research-attention snapshot, not an endorsement of NRG Oncology or any single study.
- 30 of NRG Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Adenocarcinoma is the condition NRG Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Adenocarcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NRG Oncology pipeline card: 64 registered trials from official public datasets.Report a data error.